Molecular Devices LLC

Molecular Devices LLC, a San Jose, California-based subsidiary of Beckman Coulter, Inc., sells advanced bioanalytical laboratory instruments, specialized imaging systems, electrophysiology equipment, and associated software and maintenance services to federal research agencies as a prime contractor (100% of recent awards). The company competes full-and-open across all of its federal work; no set-aside categories apply to its portfolio. Molecular Devices is a for-profit limited liability company and manufacturer of goods operating as a wholly owned subsidiary within a larger laboratory instrumentation ecosystem.

The vendor's concrete capability portfolio centers on microplate readers (SpectraMax family across multiple detection modes), high-content imaging systems (ImageXpress line for confocal and cellular screening), electrophysiology equipment (Multiclamp amplifiers and Digidata digitizers), FLIPR high-throughput cellular screening platforms, and plate washers, together with preventive maintenance, on-site performance assurance, repair services, and software support. Representative work includes a $3.86 million order from the National Center for Advancing Translational Sciences for five ImageXpress Confocal High-Content Imaging Systems and one FLIPR Penta system supporting COVID-19 antiviral research (August 2021); a $605,098.90 purchase order from the FDA Center for Food Safety and Applied Nutrition for a High Content Screening System (January 2023); a $742,212.70 firm fixed-price definitive contract from NCATS for five-year maintenance on five confocal high-content imaging systems (February 2024); and a $294,438 maintenance agreement from the National Institute of Neurological Disorders and Stroke for an ImageXpress Micro Confocal High-Content Imaging System running through November 2028 (November 2024).

Customer concentration is heavily weighted to civilian health and life sciences research agencies. The top five customers by award count account for 28% of awards and are dominated by National Institutes of Health institutes: the National Cancer Institute (80 awards, $1.1 million combined potential value), the National Institute of Allergy and Infectious Diseases (77 awards, $2.4 million), the CDC Pittsburgh facility (63 awards, $3.7 million), the NIH Office of the Director (56 awards, $453 thousand), and NIAID's acquisition office (53 awards, $981 thousand). By potential value, NCATS leads at $6.1 million across 14 awards, followed by the FDA (46 awards, $4.2 million), CDC Pittsburgh, NIAID, and the National Institute on Drug Abuse. The two rankings show complementary strength in NIH institutes and CDC, with FDA anchoring significant dollar value despite lower award count.

Molecular Devices operates almost exclusively on purchase orders and definitive contracts; five task orders sit on government-wide indefinite delivery contracts (DAAD1300D5010 carrying five task orders, BPA 36C24818A0024 with three task orders and $286 thousand in combined potential value, and three taskorders on DAAL0386C0009), and several awards flow through GSA Federal Supply Schedules (GS00F2478A and GS24F3061G). Awards under these vehicles are sole-source, typically awarded to Molecular Devices as the original equipment manufacturer of its proprietary instruments.

Activity has remained steady: 37 awards in 2022, 34 in 2023, and 41 in 2024, before declining to 20 in 2025 and 4 in 2026 year-to-date. Sixteen awards totaling $1.4 million in combined potential value face ultimate completion within the next twenty-four months and therefore present recompete exposure. The vendor's NAICS concentration is heavily in Analytical Laboratory Instrument Manufacturing (545 awards) and Other Electronic and Precision Equipment Repair and Maintenance (258 awards), with top PSC codes for Laboratory Equipment and Supplies (391 awards) and Maintenance/Repair/Rebuild of Equipment-Instruments and Laboratory Equipment (363 awards).

SCI-reportable activity is minimal: a single SCI record shows $240 thousand in invoiced revenue in FY2024 with zero FTEs reported, indicating that the vendor's federal footprint in the SCI dataset (which covers service contracts above $150,000) is negligible relative to its purchase-order-driven goods and short-term maintenance business model. This figure does not represent the vendor's total federal revenue and substantially understates the company's actual federal transaction volume, which consists primarily of equipment sales and one-off maintenance purchases below or exempt from SCI reporting thresholds. The vendor subcontracts minimally, with only two sub-awards recorded across the entire source period: a February 2024 sub to Roche Diagnostics Corporation for COVID-19 serology testing services in high-content imaging systems, and a September 2021 sub to Leidos supporting CCDC Chemical Biological Center decontamination research.

Molecular Devices' federal position is that of a specialized original-equipment-manufacturer selling proprietary instruments and consumables directly to federal research institutions on a full-and-open, non-set-aside basis. The company does not prime work for larger systems integrators and does not operate as a feeder subcontractor; when it subcontracts, it does so rarely and in support of larger primes' mandates. Its entire federal revenue model rests on the federal agencies' need to refresh, maintain, and upgrade critical laboratory infrastructure for biomedical research and public health operations, with the vast majority of awards sitting below the SCI reporting threshold and therefore invisible to federal service-contract workforce metrics.